EUVIMEDEUVIMED entdecken
Open Access

Ferritin‐based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient‐derived organoids: A novel approach for treatment

Annalisa Pia Abbinantefina, Claudia Tito, Silvia Masciarelli, Giada Tisci, Pierpaolo Ceci, Elisabetta Falvo, Veronica Ruta, Valentina Panzeri, Claudio Sette, Francesco Fazi iD, Gianni Colotti

Protein Science · 2026

DOI: 10.1002/pro.70444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein Science, 2026. Verfasst von Annalisa Pia Abbinantefina und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Section of Histology and Medical Embryology, Sapienza University of Rome, Ro…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Organoids, Pancreatic Neoplasms, Ferritins. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Next Generation EU, MUR. PRIN 2022, NextGenerationEU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activating KRAS mutations, particularly G12 variants, are key drivers in pancreatic ductal adenocarcinoma and other cancers. While KRAS was historically considered undruggable, mutant‐specific inhibitors, including non‐covalent KRAS G12D inhibitor MRTX1133, have emerged. However, efficacy and resistance remain challenges. We utilized a stimuli‐sensitive, ferritin‐derived nanomedicine platform to encapsulate high concentrations of MRTX1133, aiming for targeted delivery of the drug to KRAS‐mutated pancreatic ductal adenocarcinoma cells. This platform, designed for enhanced biodistribution and reduced off‐target effects, achieved a major efficacy over free MRTX1133 in 2D models regarding cell proliferation and KRAS inhibition pathway and, in 3D spheroid models, specifically concerning cell death. Efficacy in patient‐derived organoids was comparable. This study demonstrates the potential of this nanomedicine platform for targeted delivery of KRAS mutant‐specific inhibitors to human tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)OrganoidsPancreatic NeoplasmsFerritinsDrug CarriersCarcinoma, Pancreatic DuctalAntineoplastic AgentsAdenocarcinomaHumansCell Line, TumorCell ProliferationMutation

Stichwörter der Autor:innen

KRAS G12DMRTX1133ferritin‐based nanocarrierpancreatic adenocarcinomapatient‐derived organoids

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanFerritinsDrug CarriersAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Section of Histology and Medical Embryology, Sapienza University of Rome, Rome, Italy.
  • Institute of Molecular Biology and Pathology, Italian National Research Council, IBPM-CNR, Rome, Italy.
  • Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, Rome, Italy.
  • GSTeP Organoids Research Core Facility, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
  • Department of Wellbeing, Health and Environmental Sustainability (BeSSA), Sapienza University of Rome, Rieti, c/o Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Section of Histology and Medical…

ORCID-Profile: Francesco Fazi

Förderung

  • Next Generation EU
  • MUR. PRIN 2022
  • NextGenerationEU

Zitieren

APA

Abbinantefina, A. P., Tito, C., Masciarelli, S., Tisci, G., Ceci, P., Falvo, E., Ruta, V., Panzeri, V., Sette, C., Fazi, F., & Colotti, G. (2026). Ferritin‐based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient‐derived organoids: A novel approach for treatment. Protein Science. https://doi.org/10.1002/pro.70444

Vancouver

Abbinantefina AP, Tito C, Masciarelli S, Tisci G, Ceci P, Falvo E, et al. Ferritin‐based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient‐derived organoids: A novel approach for treatment. Protein Science. 2026. doi:10.1002/pro.70444

BibTeX
@article{Abbinantefina2026,
  author = {Abbinantefina, Annalisa Pia and Tito, Claudia and Masciarelli, Silvia and Tisci, Giada and Ceci, Pierpaolo and Falvo, Elisabetta and Ruta, Veronica and Panzeri, Valentina and Sette, Claudio and Fazi, Francesco and Colotti, Gianni},
  title = {Ferritin‐based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient‐derived organoids: A novel approach for treatment},
  journal = {Protein Science},
  year = {2026},
  doi = {10.1002/pro.70444}
}
Kostenlos starten →